cobrotoxin has been researched along with Multiple-Sclerosis* in 2 studies
1 review(s) available for cobrotoxin and Multiple-Sclerosis
| Article | Year |
|---|---|
Alpha-cobratoxin as a possible therapy for multiple sclerosis: a review of the literature leading to its development for this application.
The use of snake venom in the treatment of multiple sclerosis has been, at best, controversial. The anecdotal reports for snake venom's beneficial effects in this condition may be supportable now by recent scientific evidence. Cobratoxin, a neurotoxin obtained from the venom of the Thailand cobra, has demonstrated several pharmacological activities that strongly support its use in this application. By employing a chemical detoxification step, the neurotoxin can be rendered safe for administration to humans with minimal side effects. This modified neurotoxin has demonstrated neuromodulatory, antiviral, and analgesic activity, elements associated with the multiple sclerosis condition. Modified cobratoxin has demonstrated potent immunosuppressive activity in acute and chronic animal models of the disease. The drug is under investigation for use in adrenomyeloneuropathy and clinical trials in Multiple sclerosis are planned. Topics: Animals; Antiviral Agents; Cobra Neurotoxin Proteins; Elapid Venoms; Humans; Multiple Sclerosis; Neuroprotective Agents; Neurotoxins; Receptors, Nicotinic | 2007 |
1 other study(ies) available for cobrotoxin and Multiple-Sclerosis
| Article | Year |
|---|---|
Amelioration of acute and relapsing stages of the experimental allergic encephalomyelitis by cobra toxins.
Neurological deficits in multiple sclerosis (MS) and in experimental allergic encephalomyelitis (EAE) show demyelination of the nerve fibers, which are responsible for transmission of signals. The myelin appears to be attacked by the cells of the immune system. A viral etiology has been implicated in patients with MS. Oxidized toxins (MN) have been shown over the past 50 years to act as antiviral agents that are capable of inhibiting viral replication, and have shown promise in alleviating symptoms in EAE models of MS. The safety of these compounds has been a factor in their limited use. Development of a modified cobra toxin (MCTX) may prove more beneficial in inhibiting symptoms of EAE. In this study a modified cobra toxin (MCTX) was compared with the older oxidized toxin (MN) in an established EAE animal model. The results show that MCTX is capable of inhibiting the development as well as the relapsing phase of EAE in Lewis rats more efficiently than MN. It is possible that a safe cobra toxin can be developed with therapeutic efficacy for treatment of MS or vaccine development. Topics: Acute Disease; Animals; Cobra Neurotoxin Proteins; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Female; Injections, Subcutaneous; Multiple Sclerosis; Rats; Rats, Inbred Lew; Secondary Prevention; Severity of Illness Index; Treatment Outcome | 2006 |